… currently existing treatments. The drug is being developed by the pharmaceutical firm Novartis in … for a medicine to treat babies who are infected with malaria. Coartem Baby is …

… received Fast Track and Orphan Drug Designations from the US Food … in partnership with Medicines for Malaria Venture (MMV) – against Coartem, the current standard … potential to both treat the disease and block transmission.” Novartis said it …

… – a combination of novel drug ganaplacide with established antimalarial lumefantrine … standard treatment Coartem (artemether and lumefantrine) at achieving malaria cure. Novartis was … with the non-profit Medicines for Malaria Venture (MMV). …

… .D., President, Development and chief medical officer, Novartis. “Together with our partners … Health and Social Care. “Antimalarial drug resistance is a ticking clock … earlier this year launched Coartem Baby, the first malaria treatment for newborns and …

Novartis’ anti-malaria drug could mark … III trial. The Swiss pharma company compared GanLum (ganaplacide … , against its already approved malaria treatment, Coartem (artemether/lumefantrine), … which was developed with Medicines for Malaria Venture (MMV), is …

… the main components of Coartem. An experimental Novartis malaria drug that brings a … standard of care Coartem and compared against treatment with Coartem alone. Results … family of medicines that includes Coartem, Jagoe said. These anti-malarial drugs still …

… to pharmaceutical giant Novartis, which co-developed the drug with Medicines for Malaria Venture … combating rising resistance to existing malaria treatments. “GanLum could represent … 94% for Coartem, according to Novartis data. The drug combines ganaplacide, …

… against mutant malaria parasites associated with partial drug resistance. The treatment was also … Products, approved Novartis’ Coartem (artemether-lumefantrine) Baby, marking the first malaria medicine specifically approved …

… war against malaria with the launch of Coartem Baby, a new drug designed … specifically for infants. The breakthrough medicine … is expected to close a critical gap in treatment, safeguarding …

… has approved Coartem Baby (artemether-lumefantrine) as the first malaria treatment specifically developed … with Medicines for Malaria Venture (MMV) to address a critical treatment gap … national approvals. Novartis plans to make the treatment available on a …